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Abstract
Covered stents offer an effective bail-out strategy in vessel perforations, are an alternative to surgery for the 
exclusion of coronary aneurysms, and have a potential role in the treatment of friable embolisation-prone 
plaques. The aim of this manuscript is to offer an overview of currently available platforms and to report 
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Metallic stent platforms covered with a synthetic or biological 
membrane were originally developed in an effort to address the 
limitations of stenting, such as thrombosis and restenosis, divid-
ing the thrombogenic struts from the bloodstream and prevent-
ing smooth muscle cell migration causing neointimal hyperplasia. 
Unfortunately, neither of these two hypotheses passed the scrutiny 
of randomised clinical trials. Nevertheless, covered stents remain 
essential in catheter laboratories, since they are utilised in a num-
ber of niche situations, mainly for emergency treatment of coro-
nary perforations. This manuscript aims to offer an overview of 
currently available platforms and to report results obtained.
AUTOLOGOUS VEIN/ARTERY COVERED STENTS
These stents marked the start of the use of covered stents in coro-
naries but now remain important only from a historical point of 
view. The preparation process included isolation of a length of ves-
sel, which was then passed into the stent and sewn at both ends, in 
the middle of the outer part of the stent, so that both the luminal 
and external surfaces were covered by the graft. These stents were 
fundamentally used to improve the stent biocompatibility, accel-
erating endothelialisation and reducing the proliferative response 
of the artery wall1. Indeed, early trials in swine iliac arteries dem-
onstrated the feasibility, safety as well as low thrombosis rates of 
both artery- and vein-covered stents1,2. Clinical applications showed 
that vein-covered stents could be safely prepared and implanted 
during angioplasty but there was no obvious benefit in restenosis, 
target vessel revascularisation or event-free survival when com-
pared to bare metal stents3. In addition to the long and demanding 
preparation process, with surgical exposure of a vessel in the fore-
arm, these stents were very bulky due to their two-layer structure 
and were poorly deliverable. Still, they represented an important 
proof of concept prototype that paved the way for the introduction 
of commercial ready-made covered stents.
POLYTETRAFLUOROETHYLENE-COVERED STENTS
Polytetrafluoroethylene (PTFE) is a synthetic fluorocarbon poly-
mer with a wide range of applications in medicine, including 
manufacturing of vascular grafts in patients with or without poor 
autologous conduits. By far the most frequently used stent in 
this group is the GRAFTMASTER® (previously JoGraft; Jomed, 
and now GRAFTMASTER; Abbott Vascular, Santa Clara, CA, 
USA), which is constructed using a sandwich technique, whereby 
a layer of ePTFE is placed between two 316L stainless steel stents 
(Table 1). A similar technology is applied in the Direct-Stent® 
(InSitu Technologies Inc., St. Paul, MN, USA), while the BeGraft 
coronary stent graft system (Bentley Innomed GmbH, Hechingen, 
Germany) combines a single layer cobalt-chromium stent platform 
with an ePTFE membrane clamped at the stent ends.
POLYURETHANE-COVERED STENTS
Polyurethanes are known for their good biocompatibility together 
with their good physiochemical and mechanical properties, and 
are widely used in cardiovascular applications, such as heart 
valves and pacemaker leads. While polyurethane-covered stents 
for peripheral use have been used for decades, a dedicated coro-
nary device was only recently released (PK Papyrus; Biotronik, 
Bülach, Switzerland) based on their workhorse platform, covered 
Table 1. Covered stents available in Europe.
GRAFTMASTER Direct-Stent BeGraft PK Papyrus Aneugraft Dx
Manufacturer Abbott Vascular InSitu Technologies Bentley Innomed Biotronik ITGI Medical















CoCr (L-605) with amorphous 







6 Fr (≤4.0 mm)  
7 Fr (4.5 and 4.8 mm)
6 Fr
7 Fr
5 Fr 5 Fr (stents <4.0 mm)  
6 Fr (stents ≥4.0 mm)
6 Fr
Crimped profile 1.63-1.73 mm 1.2-1.8 mm 1.1-1.4 mm 1.18-1.55 mm 1.26-1.41 mm
Stent diameter (mm) 2.8-4.8 2.25-6.0 2.5-5.0 2.5-5.0 2.5-4.0
Stent length (mm) 16-26 10-38 8-24 15-26 13-27
Nominal implantation 
pressure
15 atm 8 atm 11 atm (2.5-4.0 mm) 
10 atm (4.5-5.0 mm)
8 atm (2.5-3.5 mm)  
7 atm (4.0-5.0 mm)
5 atm*














by a 90 µ thick polymer using electrospinning technology that 
yields a thinner and relatively flexible material.
PERICARDIUM-COVERED STENTS
The pericardium is a collagen-rich biological tissue and is broadly 
applied as a biomaterial for tissue engineering. The currently avail-
able Aneugraft® Dx stent (ITGI Medical, Or Akiva, Israel) consists 
of a flexible 316L stainless steel balloon-expandable stent, which 
is covered with a 105 µ thick single layer of equine pericardium.
Uses of covered stents
CORONARY PERFORATIONS
Coronary artery perforation is a rare but potentially disastrous 
complication of percutaneous coronary interventions (PCI). 
Management strategy is based on the severity and characteristics 
of bleeding. Ellis et al4 classified coronary perforation into three 
types: Type I, extraluminal crater without extravasation; Type II, 
pericardial or myocardial blushing; Type III, perforation ≥1 mm 
diameter with contrast streaming; and cavity spilling. While a con-
servative approach can be attempted for the least severe perfo-
rations, implantation of covered stents, coil embolisation, and 
surgery are needed for brisk ruptures5. In Type II-III perforations 
of the proximal or mid part of a coronary artery, covered stents 
allow rapid sealing of the coronary leak and are preferred as sec-
ond line treatment if haemostasis cannot be achieved by prolonged 
balloon inflation and reversal of anticoagulation (Figure 1).
There is ample literature on the use of covered stents for both 
native coronary artery and bypass graft perforations6-9, but these 
articles are often case reports or small retrospective observational 
studies, since randomisation would be impossible in this bail-out 
situation. Briguori et al compared the efficacy of the PTFE-covered 
stents for sealing of coronary perforations with that of non-covered 
stents used prior to the availability of PTFE-covered stents at their 
institution, and showed a high success rate and a favourable early 
outcome with covered stents10. In contrast, one retrospective study 
found that the use of covered stents to manage perforations was 
not associated with any reduction in adverse outcomes, such as the 
development of cardiac tamponade, need for emergency coronary 
artery bypass grafting, or in-hospital death. However, these results 
were flawed by the difference in the perforation grade between the 
groups11. Al-Lamee et al reported the management of 56 patients 
with grade III coronary perforation in two high-volume centres over 
16 years. Covered stents were deployed in 46.4% of patients (n=26) 
resulting in a high success rate with haemostasis achieved in 84.6% 
of cases (n=22), almost exclusively using PTFE-covered stents12. 
A recent report of nine cases of perforations for which balloon dila-
tation was not sufficient showed the success of the use of pericar-
dium-covered stents even in cases with complex coronary anatomy13.
PRACTICAL TIPS
An interventional cardiologist must be primed for this complica-
tion, but the scarcity of these events, especially grade III perfora-
tions, limits the ability to acquire and maintain the necessary skills 
Figure 1. Covered stents for the treatment of a perforation. Coronary 
artery perforation after deployment of two everolimus-eluting stents 
in the right coronary artery (A & B). A 3.0×16 mm PTFE-covered 
stent (GRAFTMASTER) was immediately deployed in these stents, 
completely sealing the perforation (C). Follow-up angiography at 
15 months showed the patency of the stents (D).
in managing this complication. When using oversized balloons, 
or balloons at very high pressure or in resistant lesions with dog-
boning, it is good practice to perform a contrast injection after dil-
atation while the balloon is still within the guide catheter. In this 
way a perforation is recognised early and can be sealed by advanc-
ing the same balloon back across the vessel segment. The prior-
ity is obviously to maintain haemodynamics, and brisk ruptures 
with immediate tamponade require immediate balloon dilatation 
to interrupt coronary flow and gain time to perform pericardiocen-
tesis. For ruptures not healing and causing a rapid development of 
tamponade, a second guide catheter should be considered, releas-
ing the balloon only to pass a new wire and the covered stent14. 
Caution should be taken to remove the first guide catheter slightly 
from the coronary ostium, whilst maintaining the sealing balloon 
inflated, before the engagement of the second catheter15.
Despite the decreased crossing profiles of the newer covered 
stents, these devices are still bulky and have lower deliverability 
compared to the non-covered stents. Therefore, one must be pre-
pared to face difficulties in delivering these stents, especially in tor-
tuous and calcified vessels. Stiffer wires or buddy wires are a good 
option when the delivery of the covered stent is a planned pro-
cedure but might be difficult in an emergency setting. Anchoring 
strategies or guiding catheter extensions are the alternatives; how-
ever, compatibility issues should be considered (a 6 Fr GuideLiner® 
[Vascular Solutions, Inc., Minneapolis, MN, USA] is in fact equi-
valent to 5 Fr). Second, these stents might require higher pres-
sure to ensure adequate stent expansion (GRAFTMASTER) or 














of the balloon, overexpanding it and causing tears in the membrane 
( pericardium-covered stents). Therefore, sizing the covered stent 1:1 
is essential as both overexpansion and underexpansion are not desir-
able. Covered stents offer more resistance to balloon expansion and, 
during inflation, a more prominent “dog-bone” effect is observed 
than with conventional stents16. If the balloon inflation is performed 
slowly, this facilitates trapping of friable material prone to emboli-
sation, such as thrombus or superficial lipid plaques. During infla-
tion, the membrane can shorten, which should be kept in mind for 
overlapping or adequate coverage of the perforation site17. After 
stent deployment and once the patient is haemodynamically stable, 
intracoronary imaging techniques may be useful to ensure correct 
stent expansion. After adequate sealing of the perforation, dual anti-
platelet therapy (DAPT) should be started as soon as possible. In the 
absence of evidence regarding the duration of antiplatelet therapy 
following covered stent implantation, DAPT should be continued 
long term, unless otherwise contraindicated.
EXCLUSION OF CORONARY ANEURYSMS AND FISTULAS
Coronary artery aneurysms (CAA) are relatively uncommon and 
are usually identified incidentally during angiography.
The indication for treatment and the best treatment modality still 
need to be defined. If a decision is made to exclude the aneurysm, 
covered stents can be safely used in native arteries (Figure 2) or 
grafts, including DES-related CAA in patients with a suitable anat-
omy, as an alternative to surgery18,19.
In a previous case series of seven CAA patients treated with PTFE-
covered stents, angiographic follow-up at 10±6 months showed 
good results with restenosis occurring in only one patient, necessi-
tating a repeat PCI18. Moreover, at 35±8 months clinical follow-up, 
six patients were symptom-free. In an analysis of the reported cases 
including the abovementioned series, Szalat et al reported that only 
five of the 24 patients who received stents were found to have reste-
nosis on follow-up angiography, and these patients had larger aneu-
rysms (>10 mm in diameter)20. They also compared these data with 
an earlier report reviewing the cases having operative therapy for 
CAA21: they suggested that covered stents might be a good option 
for relatively smaller CAA (5.8-10 mm in diameter) and that sur-
gery might be preferable for larger ones (above 10 mm)20. However, 
this was not a controlled study; moreover, the number of patients 
was too small and the data were heterogeneous. Therefore, these 
recommendations can only be considered as speculative.
Coronary artery fistulas are another rare anomaly, and are defined 
as abnormal communications between the coronary artery and a car-
diac chamber or another low-pressure vessel (for instance, the pul-
monary artery), bypassing the myocardial capillary bed. Coronary 
fistulas can be treated percutaneously with a number of options, and 
most frequently with coil embolisation. Covered stents can offer an 
easier solution and create a mechanical barrier between the fistula 
and the feeding vessel, but the coronary artery where the fistula 
originates has often grown too large to be approachable, and there is 
concern about exposing an otherwise normal artery to the complica-
tions associated with stent implantation. A selective niche utilisation 
in the presence of a concomitant stenosis22 or aneurysms23, or when 
the anatomy is not suitable for coil embolisation (e.g., presence of 
multiple branches)24, would be more plausible.
PRACTICAL TIPS
Occasionally, the length of the CAA can exceed the available length 
of a covered stent, so that two covered stents must be used in 
a sequential manner. Normally, the distal stent is deployed first but, 
when the stent remains unsupported in the middle of the aneurysm, 
the more proximal stent may have difficulty to advance and may dis-
tort the distal stent. Alternatively, a technique from proximal to dis-
tal sequential PTFE-covered stent implantation may be considered25.
SAPHENOUS VEIN GRAFT INTERVENTIONS
Saphenous vein graft (SVG) interventions remain technically chal-
lenging and are associated with higher rates of periprocedural myo-
cardial infarction. This is largely due to the friable, degenerated 
Figure 2. Giant coronary aneurysms post Kawasaki disease in the left anterior descending artery (LAD) of a 25-year-old male. 
A) Intravascular ultrasound view of the aneurysm (circle). B) Different coronary projection. C) Final angiography demonstrating exclusion of 













atheromatous and thrombotic debris that embolises distally, caus-
ing microvascular obstruction and vasospasm26. Although embolic 
protection devices (EPD) successfully prevent the thromboem-
bolic complications associated with PCI to SVGs, distal lesions 
are not anatomically suitable for filter or distal occlusion balloons. 
Moreover, the particles protruding through the stent struts may con-
tinue to shed debris even after the PCI is completed and the EPD is 
retrieved27. Therefore, the concept of using a covered stent to trap 
all potentially embolic debris against the vessel wall at the treatment 
site is appealing (Figure 3).
In an initial registry, PTFE-covered stents appeared to be a safe 
and efficient treatment strategy for SVG lesions with a low inci-
dence of restenosis and target vessel revascularisation28. These prom-
ising results have fuelled a number of randomised trials. However, 
these trials showed results either similar to or worse than bare 
metal stents in terms of restenosis or MACE29-31. These results were 
obtained with the double-layered GRAFTMASTER that required 
high-pressure inflation, which possibly caused more acute embolisa-
tion. When the self-expanding PTFE-covered nitinol Symbiot stent 
(Boston Scientific, Marlborough, MA, USA) was tested, results were 
equally poor32,33, leading to the withdrawal of the device.
The main results of randomised trials in the use of covered 
stents for saphenous vein graft lesions are presented in Figure 4.
The experience with pericardium-covered stents (PCS) in 
SVGs is limited to two small registries with a limited follow-up. 
The SLEEVE-I and II studies included 63 patients and 80 lesions 
and showed high procedural success rates and low MACE rates 
at 30 days in de novo or restenosed SVG lesions34.
PRACTICAL TIPS
There is also the possibility that the high profile of these stents 
may lead to significant distal embolisation when crossing the tar-
get lesion, and therefore they should not be considered as an alter-
native to EPD. A previous study by Blackman et al could not find 
significant difference in distal embolisation between the Symbiot 
stent and BMS using a FilterWire EZ™ Embolic Protection System 
Figure 3. Use of covered stents in saphenous vein graft lesions. 
A) A lesion with high signal attenuation, where (B) indicates 
a normal segment. After implantation of a pericardium-covered stent, 
optical coherence tomography confirmed exclusion of the lesion and 


















































































Figure 4. Randomised trials in the use of covered stents for saphenous vein graft lesions. *Comparison between Symbiot™ covered stent and 















(Boston Scientific)35. However, covered stents can be considered 
as devices to prevent late dislodgement of friable plaques, particu-
larly occurring in the first hours of stenting, for which EPDs are 
of no value36. There is a clear unmet need in the reconstruction of 
long occlusion of SVGs, full of thrombotic material. Long low-
profile non-thrombogenic covered stents can offer a solution when 
the approach through the native artery is truly impossible.
The possible uses of covered stents and the key points are sum-
marised in Table 2.
OTHER USES OF COVERED STENTS
Theoretically, covered stents can be deployed in the left anterior 
descending artery across the septal artery ostia to obstruct the artery 
and thus decrease the left ventricular outflow tract gradient as an 
alternative to alcohol septal ablation in patients with hypertrophic 
obstructive cardiomyopathy. Only anecdotal cases of patients 
reported immediate and long-lasting elimination of the gradient37; 
however, the dual supply of the septum makes it more likely that 
the obstruction will persist or return38, and the potential value of 
this strategy has never been properly demonstrated in a series of 
patients. Therefore, to date this strategy remains of unproven value.
Covered stents were also utilised in thrombus-laden lesions in 
native coronary arteries. Gunn et al described the treatment of 
10 lesions with the pericardium-covered stent in nine patients pre-
senting with acute coronary syndromes associated with massive 
thrombus burden, in whom conventional percutaneous and phar-
macological methods of dispersal or aspiration were not appro-
priate or successful39. Investigators reported high immediate 
procedural success, one patient with acute stent thrombosis, and 
no additional adverse events occurring in six patients who com-
pleted the 12-month follow-up. An alternative to this application 
can be the fine fabric mesh-covered stent (MGuard™; InspireMD, 
Tel Aviv, Israel)40.
Table 2. Possible uses of covered stents.





 – In Type II-III perforations of the proximal or 
mid part of a coronary artery, if haemostasis 
cannot be achieved by prolonged balloon 
inflation and reversal of anticoagulation
 – Prompt intervention is needed; a second 




 – Covered stents can be utilised to exclude the 
aneurysm from the circulation
 – Can be technically challenging, particularly if 
the aneurysm is too long
Exclusion of 
coronary fistulas
 – Covered stents create a mechanical barrier 
between the fistula and the feeding vessel
 – There is concern about exposing an otherwise 





 – Routine use is not recommended
 – Can offer an alternative in vessels with high 
risk of distal embolisation
CONCERNS ABOUT COVERED STENTS
In coronary arteries, covered stents were initially designed as 
mechanical barriers to prevent in-stent restenosis, but comparisons 
with bare metal stents showed no advantage or higher rates of in-
stent restenosis. Neointimal proliferation is frequent at the edges 
of the covered stent16,29,30, possibly related to the vessel trauma 
caused by high-pressure dilatation and lack of full PTFE cover-
age in the GRAFTMASTER stent29. On the other hand, a study 
by Papafaklis et al reported promising results in 14 patients with 
overlapping implantation of covered stents with DES at the edges. 
An angiographic follow-up at approximately 10 months showed 
restenosis only in one patient, in a segment with no overlap. At 
a mean follow-up of 21.9 months, no deaths or myocardial infarc-
tions were reported41. Hou et al investigated a similar concept in 
nine patients by assessing the PTFE-covered stents with underly-
ing longer sirolimus-eluting stents. At a 9.4 (±3.4)-month angio-
graphic follow-up, there was no stent-edge or stent-segment binary 
restenosis, while all covered stents had full and smooth neointimal 
coverage, verified by OCT42.
Thrombosis may also be a concern for the use of covered 
stents16 (Figure 5). Al-Lamee et al reported an incidence of defi-
nite stent thrombosis of 8.6% in 46 patients12. A potential mech-
anism for thrombogenicity may be the late re-endothelialisation 
of PTFE-covered stents. Despite conflicting results43, delayed 
endothelialisation is likely44; however, newer stents may have 
different properties in terms of endothelialisation. Furthermore, 
prolonged treatment with the more potent newer anti-aggregants 
Figure 5. Covered stents in saphenous vein grafts. Occlusive lesion 
of the saphenous graft (A) was successfully treated with 
a pericardium-covered stent (B). However, repeat angiography after 
four months showed total occlusion of the covered stent (C), which 













might also have a role in preventing stent thrombosis9. Finally, 
the physical barrier formed by the covered stent can compromise 
the side branch flow. Consequently, alternative options should be 
considered when a major side branch is likely to be occluded. 
Naturally, in bail-out situations, all of the concerns are offset by 
the possible gain.
Conclusion
Covered stents offer an effective bail-out strategy in vessel perfo-
rations, are an alternative to surgery for the exclusion of coronary 
aneurysms, and have a potential role in the treatment of friable 
embolisation-prone plaques. Novel stents may overcome some 
of the technical limitations of first-generation devices but greater 
experience and longer follow-up are imperative before expanding 
indications outside bail-out or niche anatomical conditions.
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